AN ARTIFICIAL INTELLIGENCE-POWERED MODEL TO PREDICT RESPONSE TO INTRAVESICAL BCG VERSUS GEMCITABINE-DOCETAXEL FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Vignesh T. Packiam(Rutgers, The State University of New Jersey), Michael J. O’Donnell(University of Iowa), Ian M. McElree(Vanderbilt University Medical Center), Viswesh Krishna(Vale (Brazil)), Vivek Nimgaonkar, Damir Vrabac(University of Pittsburgh Medical Center), Drew Watson, Waleed M. Abuzeid(University of Washington), Jordan Richards(University of Iowa), Snehal Sonawane(Rutgers, The State University of New Jersey), Stephanie Chen(Rutgers, The State University of New Jersey), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Anirudh Joshi, Anand Rajan(Johns Hopkins Medicine)
Urologic Oncology Seminars and Original Investigations
February 27, 2025
Cited by 0
Related Papers
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
|Nature Reviews Urology|2022|196
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
|International Forum of Allergy & Rhinology|2023|125
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
|JAMA Network Open|2023|116
1,1-Bis(3′-indolyl)-1-( <i>p</i> -chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth
|Molecular Cancer Therapeutics|2008|104